|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500099713 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-27 15:03:23 |
|
注册时间: Date of Registration: |
2025-03-27 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于卵泡模型的AI辅助扳机临床决策体系的建立及应用 |
|
Public title: |
Establishment and application of AI-assisted trigger clinical decision-making system based on follicular model |
|
注册题目简写: |
AI辅助扳机临床决策体系 |
|
English Acronym: |
AI-assisted trigger clinical decision-making system |
|
研究课题的正式科学名称: |
基于卵泡模型的AI辅助扳机临床决策体系的建立及应用 |
|
Scientific title: |
Establishment and application of AI-assisted trigger clinical decision-making system based on follicular model |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨静薇 |
研究负责人: |
杨静薇 |
|
Applicant: |
Jingwei Yang |
Study leader: |
Jingwei Yang |
|
申请注册联系人电话: Applicant telephone: |
+86 156 8322 1862 |
研究负责人电话:
Study leader's |
+86 156 8322 1862 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
411415434@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
411415434@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
Chongqing Health Center for Women and Children |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
重庆市渝中区七星岗金汤街重庆市妇幼保健院 |
研究负责人通讯地址: |
重庆市渝中区七星岗金汤街重庆市妇幼保健院 |
|
Applicant address: |
Jintang street 64, Yuzhong district, Chongqing,China |
Study leader's address: |
Jintang street 64, Yuzhong district, Chongqing,China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆市妇幼保健院 |
||
|
Applicant's institution: |
Chongqing health center for women and children |
||
|
研究负责人所在单位: |
重庆市妇幼保健院 |
||
|
Affiliation of the Leader: |
Chongqing health center for women and children |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)伦审(科)089号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆市妇幼保健院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Chongqing health center for women and children |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-31 00:00:00 | ||
|
伦理委员会联系人: |
李芳 |
||
|
Contact Name of the ethic committee: |
Li Fang |
||
|
伦理委员会联系地址: |
重庆市渝中区七星岗金汤街重庆市妇幼保健院 |
||
|
Contact Address of the ethic committee: |
Jintang street 64, Yuzhong district, Chongqing,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6035 4393 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
411415434@qq.com |
|
研究实施负责(组长)单位: |
重庆市妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chongqing health center for women and children |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区七星岗金汤街重庆市妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Jintang street 64, Yuzhong district, Chongqing,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市妇幼保健院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chongqing health center for women and children |
||||||||||||||||||||||
|
研究疾病: |
不孕症 |
||||||||||||||||||||||
|
Target disease: |
Infertility |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)结合患者特征、促排用药情况、B超监测下卵泡新参数等多重指标,建立AI辅助启动扳机临床决策系统,个性化制定启动扳机时间,探索其对卵子、胚胎质量及妊娠结局的影响; (2)结合AI深度学习,建立AI辅助启动扳机临床决策系统,设计软件与B超监测仪关联,实现可视化。 (3)验证AI辅助启动扳机临床决策系统,预测卵泡发育潜能及卵巢反应性,提高卵子质量、改善助孕结局。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Combining multiple indicators such as patient characteristics, ovulation-promoting medication, and new follicular parameters under ultrasound monitoring, establish an AI-assisted trigger initiation clinical decision-making system, personalize the trigger initiation time, and explore its impact on the quality of eggs, embryos, and pregnancy outcomes; (2) Combine AI deep learning to establish an AI-assisted start trigger clinical decision-making system, design software to associate with ultrasound monitors for visualization. (3) Validate the AI-assisted trigger initiation clinical decision-making system to predict follicular development potential and ovarian responsiveness, improve egg quality and assisted conception outcomes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①20至40岁之间的女性患者; ②首次进行IVF(IVF/ICSI)助孕; ③接受GnRH-ant拮抗剂促排方案; ④诊断为盆腔环境、输卵管因素不孕或男性因素不孕。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Female patients between 20 and 40 years old; 2. Undergoing IVF (IVF/ICSI) assisted conception for the first time; 3. Receiving GnRH-antagonist ovulation promotion program; 4. Diagnosed with pelvic environment, tubal factor infertility or male factor infertility. |
||||||||||||||||||||||
|
排除标准: |
①染色体核型异常、PGT周期; ②卵巢功能异常、多囊卵巢综合症(PCOS); ③子宫内膜异位症、纵隔子宫、单角子宫、宫颈功能不全等先天性因素; ④严重代谢和内分泌疾病患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Chromosome abnormalities, PGT cycles; 2. Abnormal ovarian function, polycystic ovary syndrome (PCOS); 3. Congenital factors such as endometriosis, mediastinal uterus, unicornuate uterus, cervical insufficiency; 4. Patients with severe metabolic and endocrine diseases. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-31 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用抽签方式将受试者随机分入实验组与对照组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Subjects were randomly divided into the experimental group and the control group by drawing lots |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲,对受试者设盲 |
|
Blinding: |
Single-blind, blinding subjects |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
将于2025年6月1日起在临床试验公共管理平台填入原始数据(ResMan;http://www.medresman.org.cn/login.aspx) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Original data will be populated in the public management platform for clinical trials starting June 1, 2025(ResMan;http://www.medresman.org.cn/login.aspx) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1、数据采集:病例记录表 2、数据管理:临床试验公共管理平台ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1.Data Acquisition: Case record form 2.Data management: Clinical Trial Management Public Platform |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |